CANF - Can-Fite BioPharma Ltd.

NYSE American - NYSE American Delayed Price. Currency in USD
2.1500
+0.1000 (+4.88%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close2.0500
Open2.0500
Bid2.0800 x 2200
Ask2.1300 x 3200
Day's Range2.0500 - 2.2500
52 Week Range1.0800 - 4.9500
Volume461,188
Avg. Volume1,163,584
Market Cap21.398M
Beta (5Y Monthly)1.12
PE Ratio (TTM)N/A
EPS (TTM)-3.3600
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.00
  • Can-Fite Receives Notice of Allowance for Namodenoson Patent in the Treatment of NASH & NAFLD from U.S. Patent and Trademark Office
    Business Wire

    Can-Fite Receives Notice of Allowance for Namodenoson Patent in the Treatment of NASH & NAFLD from U.S. Patent and Trademark Office

    Can-Fite Receives Notice of Allowance for Namodenoson Patent in the Treatment of NASH & NAFLD from U.S. Patent and Trademark Office

  • Can-Fite Reports Additional Findings from Successful Phase II NASH Study: 25 mg Dose of Namodenoson Significantly Reduced Liver Fat and Fibrosis
    Business Wire

    Can-Fite Reports Additional Findings from Successful Phase II NASH Study: 25 mg Dose of Namodenoson Significantly Reduced Liver Fat and Fibrosis

    Can-Fite Reports Additional Findings from Successful Phase II NASH Study: 25 mg Dose of Namodenoson Significantly Reduced Liver Fat and Fibrosis

  • Can-Fite Announces Pre-IND Submission to U.S. FDA for Piclidenoson in the Treatment of COVID-19 Infected Patients with Moderate-to-Severe Symptoms
    Business Wire

    Can-Fite Announces Pre-IND Submission to U.S. FDA for Piclidenoson in the Treatment of COVID-19 Infected Patients with Moderate-to-Severe Symptoms

    Can-Fite Announces Pre-IND Submission to U.S. FDA for Piclidenoson in the Treatment of COVID-19 Infected Patients with Moderate-to-Severe Symptoms

  • Top Ranked Momentum Stocks to Buy for April 28th
    Zacks

    Top Ranked Momentum Stocks to Buy for April 28th

    Top Ranked Momentum Stocks to Buy for April 28th

  • Top Ranked Momentum Stocks to Buy for April 27th
    Zacks

    Top Ranked Momentum Stocks to Buy for April 27th

    Top Ranked Momentum Stocks to Buy for April 27th

  • Can Fite to Conduct Investor Call to Review Positive Phase II NASH Data on Thursday, April 16, 2020 at 4:05 p.m. ET
    Business Wire

    Can Fite to Conduct Investor Call to Review Positive Phase II NASH Data on Thursday, April 16, 2020 at 4:05 p.m. ET

    Can Fite to Conduct Investor Call to Review Positive Phase II NASH Data on Thursday, April 16, 2020 at 4:05 p.m. ET

  • Biocept To Begin COVID-19 Testing; BioCryst, Athersys, Can-Fite To Research Potential Treatments In Clinics
    Benzinga

    Biocept To Begin COVID-19 Testing; BioCryst, Athersys, Can-Fite To Research Potential Treatments In Clinics

    As the COVID-19 pandemic continues to ravage the globe, having claimed over 115,000 lives, health care companies have are pursuing diagnostics tests, potential vaccines and therapies.The following companies provided updates Monday on their coronavirus programs.Biocept To Accept COVID-19 Testing Requests San Diego, California-based Biocept Inc (NASDAQ: BIOC), a provider of liquid biopsy tests, said in a Thursday press release that it intends to begin accepting physician-ordered COVID-19 molecular diagnostic testing requests for processing beginning April 15. Biocept said it has partnered with a national clinician network to accept patient samples and may obtain additional agreements as test capacity is increased. The company's lab will use the FDA-approvedThermo Fisher Scientific Inc. (NYSE: TMO) Scientific TaqPath and kit for SARS-CoV2, which received Emergency Use Authorization from the FDA. "I am very thankful to our laboratory team for stepping up and quickly validating COVID-19 testing, in addition to the vital work we do each day for patients diagnosed with cancer," Biocept CEO Mike Nall said in a statement. Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter.See also: The Week Ahead In Biotech: Urogen FDA Decision, Amarin, J&J Earnings And More COVID-19 Updates BioCryst Opens Enrollment In Brazilian Trial Of Potential SARS-CoV-2 Treatment BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) said it has opened enrollment into a randomized, double-blind, placebo-controlled clinical study to assess the efficacy and antiviral effects of its galidesivir in patients with COVID-19.The trial will be funded by the National Institute of Allergy and Infectious Diseases, according to the company. Galidesivir is an investigational broad-spectrum antiviral drug that was found to be safe and well-tolerated in an Phase 1 trial conduced in healthy subjects, BioCryst said. It also showed broad-spectrum activity in labs against more than 20 RNA viruses belonging to nine families, including the coronaviruses that cause MERS and SARS.The company said the planned trial will be conducted in Brazil under a U.S. IND, and the protocol has been approved by the Brazilian regulatory agencies."We have begun to see COVID-19 cases in Brazil, and we have a good opportunity to enroll and treat patients earlier in their disease course to determine if galidesivir can benefit patients with COVID-19," said Dr. Esper Kallas, principal investigator of the study.Athersys Gets FDA Nod For Pivotal Phase 2/3 Study Of MultiStem Therapy For COVID-19 Induced ARDS Athersys Inc (NASDAQ: ATHX) said the FDA has authorized the company to initiate a Phase 2/3 pivotal study to assess the safety and efficacy of MultiStem therapy in subjects with moderate-to-severe acute respiratory distress syndrome, or ARDS, induced by the COVID-19 disease.Since the program falls under the company's current IND application for its completed MUST-ARDS study, it is not required to file a new IND.Athersys said it plans to open the first clinical sites for recruitment of the MACOVIA study this quarter. Can-Fite To Begin Enrollment, Dosing In COVID-19 Trial Immediately Can-Fite BioPharma Ltd. (NYSE: CANF) said it has received approval from the Institutional Review Board at Israel's Rabin Medical Center to initiate a pilot clinical study of its drug candidate Piclidenoson for the treatment of moderate-to-severe symptoms in coronavirus infected patients.The company announced in late March that it has submitted Piclidenoson to the institute for a COVID-19 compassionate use program.Patient enrollment and dosing will begin immediately, the company said."Piclidenoson's anti-viral, anti-inflammatory, and anti-rheumatic properties combined with its excellent safety profile make it a strong candidate for the potential treatment of coronavirus," Dr. Pnina Fishman, CEO of Can-Fite, said in a statement. Price Action * Biocept shares were jumping 63.3% to 58 cents at the time of publication Monday. * BioCryst shares were gaining 21.27% to trade at $2.51. * Athersys was moving up 8.59% to $3.16. * Can-Fite shares were surging 44.83% to $2.10. Related Link: Morgan Stanley Downgrades Lilly On Valuation, Says Growth, Pipeline Potential Balanced By Stock Premium See more from Benzinga * The Daily Biotech Pulse: Novartis Scraps Deal To Sell Sandoz Assets, Nevro Pre-Announces Q1 Shortfall, Affimed Granted Orphan Drug Designation * The Daily Biotech Pulse: InflaRx Begins Human Testing For COVID-induced Pneumonia, Chembio, Becton Dickinson Launch Coronavirus Tests * The Daily Biotech Pulse: Amarin Faces Legal Setback, Milestone Payment Kicks In For CytomX, Savara, Reata Disclose COVID-19 Disruptions(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Can Fite Received Approval for COVID-19 Clinical Trial in Israel, Patient Enrollment and Dosing to Commence Immediately
    Business Wire

    Can Fite Received Approval for COVID-19 Clinical Trial in Israel, Patient Enrollment and Dosing to Commence Immediately

    Can Fite Received Approval for COVID-19 Clinical Trial in Israel, Patient Enrollment and Dosing to Commence Immediately

  • Can-Fite Reports Positive Top Line Results from its Phase II NASH Study with Namodenoson
    Business Wire

    Can-Fite Reports Positive Top Line Results from its Phase II NASH Study with Namodenoson

    Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory and liver diseases, today announced that its Phase II exploratory NAFLD/NASH study with Namodenoson achieved its efficacy endpoints, while continuing to demonstrate a good safety profile.

  • Can-Fite Implements Interim Analysis for its Phase III Psoriasis Trial with Data Expected Q4 2020
    Business Wire

    Can-Fite Implements Interim Analysis for its Phase III Psoriasis Trial with Data Expected Q4 2020

    Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, announced today it is implementing an interim analysis of the Phase III Comfort™ trial designed to evaluate the Company’s drug candidate, Piclidenoson, in the treatment of moderate-to-severe plaque psoriasis. Following the independent data monitoring committee’s evaluation of the data, Can-Fite expects to announce interim results in the fourth quarter of 2020.

  • Can-Fite Reports 2019 Financial Results & Provides Clinical Development Update
    Business Wire

    Can-Fite Reports 2019 Financial Results & Provides Clinical Development Update

    Can-Fite Reports 2019 Financial Results & Provides Clinical Development Update

  • Can-Fite: Piclidenoson is Submitted for Compassionate Use Treatment for Coronavirus Patients in Israel
    Business Wire

    Can-Fite: Piclidenoson is Submitted for Compassionate Use Treatment for Coronavirus Patients in Israel

    Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, announced today that it has submitted Piclidenoson for a compassionate use program to treat coronavirus patients to the Institutional Review Board at Rabin Medical Center. If approved, the compassionate use program will be led by Dr. Dror Diker, M.D., Head of Internal Medicine D at the Rabin Medical Center. Patients would be treated at Rabin’s Golda Hasharon Campus which is currently positioned to treat coronavirus patients in a specialized setting.

  • Can-Fite to Participate in Digital Bio-Europe Spring Partnering Conference; Looks to Partner on Co-Development of Piclidenoson for Coronavirus Treatment
    Business Wire

    Can-Fite to Participate in Digital Bio-Europe Spring Partnering Conference; Looks to Partner on Co-Development of Piclidenoson for Coronavirus Treatment

    Can-Fite to Participate in Digital Bio-Europe Spring Partnering Conference; Looks to Partner on Co-Development for Coronavirus Treatment

  • Can-Fite: Progress in Compassionate Use Program Treating Advanced Liver Cancer Patients with Namodenoson
    Business Wire

    Can-Fite: Progress in Compassionate Use Program Treating Advanced Liver Cancer Patients with Namodenoson

    Can-Fite: Progress in Compassionate Use Program Treating Advanced Liver Cancer Patients with Namodenoson

  • The Latest Coronavirus Developments From Biotechs: La Jolla Provides Giapreza In Italy, Enanta Researches Antivirals
    Benzinga

    The Latest Coronavirus Developments From Biotechs: La Jolla Provides Giapreza In Italy, Enanta Researches Antivirals

    The following are the latest biotech announcements from late Thursday and Friday morning on the development of products targeting the coronavirus. I-Mab ADR (NASDAQ: IMAB)The Shanghai-based biopharma said Friday it is initiating the development pf TJM2 to treat cytokine storms in severe and critically ill patients caused by COVID-19. TJM2 is a neutralizing antibody against human granulocyte-macrophage colony stimulating factor, an important cytokine that plays a key role in acute and chronic inflammation.The company said it is awaiting FDA acceptance of an investigational new drug application. La Jolla Pharmaceutical Company (NASDAQ: LJPC)La Jolla said Friday that it is providing Giapreza in Italy for compassionate use in patients with septic shock associated with COVID-19. Giapreza was approved by the FDA in 2017 as a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock.It was later approved by the European Commission for treating refractory hypotension in adults with septic or other distributive shock.The drug, though approved by the EC, is not yet commercially available.Italian law allows authorized medicines for life-threatening and rare illnesses to be made available prior to commercial launch, according to La Jolla. Enanta Pharmaceuticals Inc (NASDAQ: ENTA)Enanta Pharma said Friday it has initiated a program to discover direct-acting antiviral drug candidates for treating patients infected with the coronavirus. The company said it is drawing upon its expertise in virology.The company is also screening compounds from its antiviral compound library for potential activity against COVID-19.See also: How Close Are Biotechs To Bringing A COVID-19 Treatment To Market? CAN FITE BIOPHARMA ADR REP 30 ORD (NYSE: CANF)Canadian biotech Can-Fite said Friday it is entering into a collaborative research agreement with the Lewis Katz School of Medicine at Templeton University, Philadelphia, to support research directed by Dr. Kamel Khalili, who is exploring the antiviral activity of piclidenoson on the coronavirus' viral load in a mammalian cell model system as a first step.Piclidenoson is Can-Fite's investigational Phase 3 asset currently being evaluated for rheumatoid arthritis and moderate-to-severe psoriasis.Roche Holdings AG Basel ADR Common Stock (OTC: RHHBY)Roche said Friday that the FDA has issued an Emergency Use Authorization for the cobas SARS-CoV-2 Test.Eli Lilly And Co (NYSE: LLY)Lilly said Thursday that it's collaborating with AbCellera, a privately held company developing therapeutic antibodies, to co-develop antibody products for treating COVID-19.Meanwhile, Opko Health Inc. (NASDAQ: OPK) and Aytu Bioscience Inc (NASDAQ: AYTU) announced updates to their COVID-19 initiatives.Opko said Friday that its BioReference Labs subsidiary has begun accepting specimens for testing of COVID-19 from health care providers, clinics and health systems throughout the U.S.The company has announced a partnership with the New York State Department of Health for the first public drive-through testing facility on the East Coast. BioReference Labs is also planning to offer up to 5,000 tests a day at additional testing sites to be set up next week.Aytu announced the establishment Friday of a COVID-19 inquiry procedure to ensure the company adequately responds to inbound inquires from professionals and the public.The company said Tuesday that it clinched a distribution deal for a COVID-19 IgG/IgM Rapid Test.Biotech Price Action * La Jolla was rallying 8.92% to $4.15 * Can-Fite shares were rallying 5.26% to $1.40. * Lilly shares were advancing 5.09% to $132.44. * Opko Health was jumping 39.08% to $1.98. * Aytu was slipping 20.65% to $1.46. * OTC-listed Roche shares were up 7.77% at $38.43. Related Link: Inovio Continues To Rip Higher On Gates Foundation Funding For DNA Vaccine Delivery Device See more from Benzinga * The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO * The Daily Biotech Pulse: NY State Endorses Mallinckrodt's Opioid Settlement, Kamada To Work On COVID-19 Treatment(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Benzinga

    Benzinga Pro's Top 5 Stocks To Watch For Fri., Mar. 13, 2020: GLD, OPK, IBIO, CPB, CANF

    Benzinga Pro's Stocks To Watch For Friday * SPDR Gold Shares (GLD) \- Gold has not been serving as a store of value during this week's market rout. While the S&P 500 has been down about 5%, gold has been down about 6%. With the S&P 500 futures hitting a limit-up breaker Friday morning (up ~5%), gold is up about 0.7%. * OPKO Health (OPK) \- Shares were up 50% Friday following a 15% decline Thursday. New York Governor Cuomo said the State is contracting with the company's BioReference Laboratories unit to run 5,000 tests/day for coronavirus. Additionally, the company announced its BioReference Labs is now accepting specimens for testing coronavirus from healthcare providers throughout the US. * iBio (IBIO) \- The stock was up 30% after the company filed four provisional patent applications for its virus-like particle platform technology in conjunction with FastPharming System for treating and preventing coronavirus infection. * Campbell Soup (CPB) \- Shares were up about 3% to around $49 with the broader markets despite a Goldman Sachs downgrade to Sell. The firm set a $47 price target. * Can-Fite (CANF) \- The company announced it will explore anti-coronavirus effects of its piclidenoson in collaboration with Lewis Katz School of Medicine. The stock was up about 20%.See more from Benzinga * Benzinga Pro's Top 5 Stocks To Watch For Mon., Mar. 9, 2020: XOM, GLD, BA, TSLA, SPEX * Benzinga Pro's Top 5 Stocks To Watch For Thurs., Mar. 5, 2020: ZM, MRVL, LUV, CODX, CANF * Benzinga Pro's Top 5 Stocks To Watch For Tues., Feb. 4, 2020: GOOGL, DIS, EBAY, F, IBIO(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • TheStreet.com

    Can-Fite Surges on Study Hopes for Arthritis Drug in Coronavirus Treatment

    Can-Fite said its lead drug, Piclidenoson, is in a phase III study for rheumatoid arthritis treatments, but could possibly be used on coronavirus patients.

  • Can-Fite to Explore the anti-Coronavirus Effects of Piclidenoson in Collaboration with Lewis Katz School of Medicine at Temple University
    Business Wire

    Can-Fite to Explore the anti-Coronavirus Effects of Piclidenoson in Collaboration with Lewis Katz School of Medicine at Temple University

    Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, is entering into a collaborative research agreement with the Lewis Katz School of Medicine at Temple University, Philadelphia, USA. The agreement will support research directed by Dr. Kamel Khalili, aimed to explore anti-viral activity of Piclidenoson on Coronaviruses viral load in a mammalian cell model system as a first step.

  • Biotech Stock Roundup: NVAX, CANF Up on Coronavirus Treatment Updates & More
    Zacks

    Biotech Stock Roundup: NVAX, CANF Up on Coronavirus Treatment Updates & More

    The biotech sector is in focus with pipeline updates from companies evaluating treatments for the novel COVID-19.

  • Can-Fite: New Pre-clinical Studies Demonstrate Inhibition of Fat Cell Expansion by Cannabis Derived CBD
    Business Wire

    Can-Fite: New Pre-clinical Studies Demonstrate Inhibition of Fat Cell Expansion by Cannabis Derived CBD

    Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address autoimmune inflammatory, liver and metabolic diseases, today announced new pre-clinical data demonstrating that cannabis derived CBD enriched fractions, supplied by Univo Pharmaceuticals, inhibit the expansion of human fat cells (pre-adipocytes) by 60%, a result that points towards the potential anti-obesity effect of this agent. Although it is already documented that cannabis derived compounds possess anti-obesity effect, the novel data presented by the Company demonstrates the anti-obesity effect at low nano-molar concentrations. Low CBD concentrations are known to be safe and well accepted in humans.

  • Can-Fite (CANF) to Explore RA Drug for Coronavirus Treatment
    Zacks

    Can-Fite (CANF) to Explore RA Drug for Coronavirus Treatment

    Can-Fite (CANF) announces plans to explore piclidenoson for the treatment of coronavirus.

  • Benzinga

    Benzinga Pro's Top 5 Stocks To Watch For Thurs., Mar. 5, 2020: ZM, MRVL, LUV, CODX, CANF

    Benzinga Pro's Stocks To Watch For Thursday * Zoom Video Communications, Inc. (ZM) \- Shares were down 7% despite a Q4 beat and Q1, FY21 guidance that was strong. Stephens analyst Ryan MacWilliams Wednesday after the report noted year-over-year sales growth was slightly below what the buy-side had been expecting. He also suggested investors "remain focused on management commentary surrounding user growth post-coronavirus outbreak." * Marvell Technology Group Ltd. (MRVL) \- The stock was up 8% following better-than-expected Q4 results and inline-to-slightly-better guidance. * Southwest Airlines Co. (LUV) \- Gave a warning "in recent days, the company has experienced a significant decline in customer demand, as well as an increase in trip cancellations..." amid the coronavirus outbreak. The company said it expects Q1 operating sales to be negatively impacted by $200 million to $300 million. Shares were down 3% ahead of the open. * Co-Diagnostics, Inc. (CODX) \- Shares were up 26% following a company press release which highlighted "added demand" for its coronavirus test shipments. While no specific terms/quantities were included in the release, the company said it received "numerous" requests from US labs for the test kit. * Can-Fite BioPharma Ltd. (CANF) \- The company disclosed it is exploring a collaboration to test two drug candidates for use against coronavirus. Shares were up 36%.See more from Benzinga * Benzinga Pro's Top 5 Stocks To Watch For Mon., Mar. 2, 2020: GILD, BIDU, CODX, MRKR, APDN * Benzinga Pro's Top 5 Stocks To Watch For Wed., Feb. 19, 2020: BLPH, GRPN, VIVE, CODX, GNPX * Benzinga Pro's Top 5 Stocks To Watch For Tues., Feb. 11, 2020: DISH, HAS, SHOP, CODX, FB(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • The Daily Biotech Pulse: Trevana Pain Drug Resubmission Accepted For Review, Can-Fite To Explore Treatment For COVID-19
    Benzinga

    The Daily Biotech Pulse: Trevana Pain Drug Resubmission Accepted For Review, Can-Fite To Explore Treatment For COVID-19

    Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 4) * 89bio Inc (NASDAQ: ETNB) * Arcus Biosciences Inc (NYSE: RCUS) * Arcturus Therapeutics Ltd (NASDAQ: ARCT)(announced a partnership with Duke-NUS Medical School to develop a COVID-19 vaccine for Singapore) * Cue Biopharma Inc (NASDAQ: CUE) * IGM Biosciences Inc (NASDAQ: IGMS) * Inovio Pharmaceuticals Inc (NASDAQ: INO) * Ocular Therapeutix Inc (NASDAQ: OCUL)(reacted to its preliminary fourth-quarter results and interim data from a Phase 1 study evaluating its eye implant OTX-TKI in patients with wet age-related macular degeneration) * Quest Diagnostics Inc (NYSE: DGX) * Regeneron Pharmaceuticals Inc (NASDAQ: REGN)(CEO Leonard Schleifer reportedly told CNBC the company hopes to produce COVID-19 treatment candidate that could be ready for human testing by August) * Revolution Medicines Inc (NASDAQ: RVMD) (IPOed mid-February) * SpringWorks Therapeutics Inc (NASDAQ: SWTX) * Syndax Pharmaceuticals Inc (NASDAQ: SNDX)(reacted to the company's fourth-quarter results) * Syneos Health Inc (NASDAQ: SYNH) * Viela Bio Inc (NASDAQ: VIE)Down In The Dumps (Biotech Stocks Hitting 52-week lows on March 4) * Alterity Therapeutics Ltd (NASDAQ: ATHE) * AngioDynamics, Inc. (NASDAQ: ANGO) * Aptevo Therapeutics Inc (NASDAQ: APVO) * CASI Pharmaceuticals Inc (NASDAQ: CASI) * Enlivex Therapeutics Ltd (NASDAQ: ENLV) * Evogene Ltd (NASDAQ: EVGN)(reacted to fourth-quarter results) * Evolus Inc (NASDAQ: EOLS)(reacted to comments by Korean drug maker Medytox about an ITC case brought up by the company against Daewoong and partner Evolus on intellectual property related to Medytox' botulinum toxin) * Mylan NV (NASDAQ: MYL) * Orthofix Medical Inc (NASDAQ: OFIX) * Passage Bio Inc (NASDAQ: PASG)(IPOed last week) * Titan Medical Inc. (NASDAQ: TMDI)See also: Attention Biotech Investors: Mark Your Calendar For These March PDUFA Dates Stocks In Focus Co-Diagnostics' COVID-19 Detection Kit Demand Surges Co-Diagnostics Inc (NASDAQ: CODX) said demand, both domestic and international, surged for its COVID-19 detection kits in recent weeks, leading to increased product shipments. The increase comes after the FDA changed its policy Feb. 20 and the number of cases testing positive for the disease burgeoned worldwide.The stock was surging 27.17% to $15.26 in pre-market trading.Castle Biosciences Gets First Patent For Skin Cancer Gene Expression Profile Test Skin cancer diagnostic company Castle Biosciences Inc (NASDAQ: CSTL) said the U.S. patent office has issued it the first U.S. patent related to the DecisionDx -Melanoma gene expression profile test for patients with cutaneous melanoma.FDA Accepts Trevena's Resubmitted NDA for Pain Drug Trevena Inc (NASDAQ: TRVN) said the FDA has acknowledged the receipt of and accepted the resubmitted NDA for intravenous oliceridine, its lead investigational asset, for the management of moderate-to-severe acute pain. The PDUFA date has been set for Aug. 7.In pre-market trading, shares were rising 12.35% to 91 cents.Can-Fite To Explore Treatment For COVID-19 Can-Fite BioPharma Ltd. (NASDAQ: CANF) said it is exploring a collaboration to explore if its investigational asset Piclidenoson, being evaluated for autoimmune inflammatory disease, is effective against coronavirus following reports that rheumatoid arthritis drugs have been introduced for the treatment of the same.The stock was jumping 26.28% to $1.97 in pre-market trading.RA Medical Says NYSE Accepts Plan to Regain Compliance RA Medical Systems Inc (NYSE: RMED) said the NYSE has accepted the company's business plan to regain compliance with the NYSE listing standards. Late last year, the company was notified by the NYSE regarding flouting of listing standards pertaining to average market capitalization being less than $50 million over a recent consecutive 30 days.MacroGenomics' Chief Medical Officer Resigns to Pursue Another Opportunity MacroGenics Inc (NASDAQ: MGNX) announced the resignation of Jon Wigginton as its SVP, Clinical Development & Chief Medical Officer, effective March 27, as he pursues a new opportunity. The role will be assigned on an interim basis to Ezio Bonvini, who is currently serving as SVP, Research and Chief Scientific Officer, the company said.Morphosys To Issue Additional Shares For Subscription By Incyte As Part of Tafasitamab Licensing Deal Morphosys Ag (NASDAQ: MOR) said its Management Board has resolved to increase the share capital of the company by issuing 907,441 new ordinary shares from the authorized capital to facilitate purchase of 3.63 million ADSs by Incyte Corporation (NASDAQ: INCY). The newly issued shares represent about 2.84% of the registered share capital of MorphoSys prior to the consummation of the capital increase.View more earnings on TRVNIncyte's purchase of ADSs amounting to $150 million or $41.32 per ADS is part of the consideration due to MorphoSys for the former acquiring licensing rights to develop and commercialize the latter's investigational compound tafasitamab.In pre-market trading, MorphoSys shares were slipping 3.70% to $28.89.Earnings Specialty pharma company Opiant Pharmaceuticals Inc (NASDAQ: OPNT), which develops treatment for treating addictions and drug overdose, reported fourth-quarter revenues of $7.7 million compared to $4.8 million in the fourth quarter of 2018. The company reversed to a profit of 20 cents per share from a loss of $2.49 per share last year, while analysts had estimated a loss of $2.13 per share, on average.The stock rallied 17.09% to $13.70 in after-hours trading.Offerings BridgeBio Pharma Inc (NASDAQ: BBIO) priced the upsized offering of $475 million aggregate principal amount of 2.50% convertible senior notes due 2027 in a private offering to qualified institutional buyers. The company said the notes will bear interest at a rate of 2.50% per year, payable semi-annually in arrears on March 15 and Sept. 15 of each year. Beginning Sept. 15, 2020.The company estimates to raise net proceeds of about $463.7 million from the offering.On The Radar Earnings * Arbutus Biopharma Corp (NASDAQ: ABUS) (before the market open) * BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) (before the market open) * Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT) (before the market open) * Xtant Medical Holdings Inc (NYSE: XTNT) (before the market open) * Fulcrum Therapeutics Inc (NASDAQ: FULC) (before the market open) * Syros Pharmaceuticals Inc (NASDAQ: SYRS) (before the market open) * Obseva SA (NASDAQ: OBSV) (before the market open) * OptiNose Inc (NASDAQ: OPTN) (before the market open) * Caladrius Biosciences Inc (NASDAQ: CLBS) (after the close) * Eton Pharmaceuticals Inc (NASDAQ: ETON) (after the close) * BioNano Genomics Inc (NASDAQ: BNGO) (after the close) * Corvus Pharmaceuticals Inc (NASDAQ: CRVS) (after the close) * Eloxx Pharmaceuticals Inc (NASDAQ: ELOX) (after the close)See more from Benzinga * GenMark Spikes Higher On COVID-19 Test Kit Shipment * The Daily Biotech Pulse: GenMark Diagnostics Ships COVID-19 Test Kits, Karyopharm To Offer Shares, And More * How The COVID-19 Outbreak Is Benefiting Biotech Investors(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Can-Fite Updates on Clinical Milestone for its Phase III Rheumatoid Arthritis Study with Piclidenoson; Drugs Combating Rheumatoid Arthritis are Currently Introduced for the Treatment of the Coronavirus
    Business Wire

    Can-Fite Updates on Clinical Milestone for its Phase III Rheumatoid Arthritis Study with Piclidenoson; Drugs Combating Rheumatoid Arthritis are Currently Introduced for the Treatment of the Coronavirus

    Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, announced today that data from the interim analysis of Piclidenoson in its Phase III clinical study is expected to be released during Q4 2020. Moreover and in line with the reports that rheumatoid arthritis (RA) drugs have been introduced for the treatment of the Coronavirus, the Company is now exploring a collaboration to look at the effect of Piclidenoson against Coronavirus. Can Fite drug candidates possess anti-viral effect protected by a US patent US7589075.